Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Asia Pacific Newborn Screening Market Insights
Infants are most vulnerable to diseases such as polio, epilepsy, encephaliphitis, asthma, COPD and other respiratory disease, diarrhea, leukemia, anemia, and other rare diseases that results in substantial economic burden.
Newborn screening describes various tests that are performed during first few hours or days of an infant’s life. These tests have the potential of preventing severe health problems and prevents from death. According to American Academy of Pediatrics: 2018, newborn screening and diagnosis are important to ensure that all babies who are deaf or hard of hearing are identified as soon as possible. According to same source, 1 to 3 out of every 1,000 babies born in the U.S. have hearing level outside the typical range. When these babies receive early intervention services, it makes a big difference in their communication and language development in the future.
Asia Pacific newborn screening market size was valued at US$ 171.3 million in 2017 and is expected to witness a CAGR of 12.7% during the forecast period (2018 – 2026).
Figure 1. Asia Pacific Newborn Screening Market Value (US$ Mn) Analysis and Forecast and Absolute $ Opportunity
Source: Coherent Market Insights Analysis (2018)
Increasing government initiatives is expected to drive growth of the Asia Pacific newborn screening market
Increasing engagement programs by various government healthcare regulatory bodies for newborn screening and its deployment for wider population base are expected to drive growth of the market during the forecast period. For instance, in June 2014, PerkinElmer, a company engaged in the diagnostics, life science research, food, environmental and industrial testing area, entered into an exclusive collaboration with China's National Health and Family Planning Commission (NHFPC) to implement a three-year training program for newborn screening.
The National Maternal & Children Health Surveillance Office (NMCHSO) is working with PerkinElmer, to increase availability and adoption of newborn screening in China, particularly via expansion in more rural areas.
Moreover, technological advancements in tandem mass spectrometry, colorimetric analysis test, fluorescence analysis test, enzyme or liquid chromatography, and various immunological assays and other analysis and high adoption rate of newborn screening with new technology are factors that are expected to drive growth of the market. In October 2018, LifeCell International, India’s leading stem cell bank and mother & baby diagnostics company, launched RightStart, the world’s first Integrated DNA testing for newborn screening to detect over 50 medical conditions.
However, lack of improvement in healthcare infrastructure and trained professionals is a major factor hindering growth of the Asia Pacific newborn screening market. Newborn screening is still not widely adopted in Asia Pacific region and requires more development and awareness. Countries in Asia Pacific region have high population and less number of trained professionals. High population with low and middle-income level and poor quality health services are hindering growth of the market.
Asia Pacific Newborn Screening Market- Country Analysis
On the basis of country, Asia Pacific newborn screening market is segmented into China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific.
China holds the major share due to innovative and new initiatives by government for implementing various newborn screening programs. Currently Congenital Hypothyroidism (CH) and Phenylketonuria (PKU) and hearing loss are included as national wide screening program in China, which is also mandatory for all newborn.
In addition to this, more than 150 Newborn Screening (NBS) labs in China offer screening program for Congenital Adrenal Hyperplasia (CAH) and Glucose-6-Phosphate Dehydrogenase Deficiency (G-6-PDD), and about 11 million babies had been screened for CAH and G6PD in 2017.
India is expected to witness significant growth in the Asia Pacific newborn screening market, owing to high birth rate in this region. For instance, according to the World Health Organization (WHO) 2016, India’s total population was 1,324,171,000, which is second-largest in Asian countries after China. Newborn birth rate in India is around 34 births per second and 2,062 births per hour.
Figure 2: Asia Pacific Newborn Screening Market Share (%), By Country
Source: Coherent Market Insights Analysis (2018)
Asia Pacific Newborn Screening Market- Competitive Landscape
Key players operating in the Asia Pacific newborn screening market include Medtronic plc, Agilent Technologies, Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.